OptimizeRx (OPRX) 10-Q2024 Q1 Quarterly report

Filed: 15 May 24, 5:01pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: accrual, accuracy, added, approach, arrangement, assessed, aware, back, carried, clause, clinical, collateral, complement, complementary, compliance, complimentary, comprised, consulting, content, correct, cumulative, DAAP, deliver, delivered, disposal, disposed, diverse, doubtful, dynamic, EBITDA, elimination, ensure, equipment, equivalent, ERx, establishing, expenditure, experience, failure, FASB, flat, footprint, frequently, FTE, history, input, leading, leverage, licensing, maintenance, mandatory, media, multiplied, nonrefundable, November, obtain, omnichannel, ordinary, payer, permanent, permitted, prepayment, professional, provision, qualification, rebate, reconciliation, referred, Registration, regularly, reimbursement, resell, reselling, resolved, response, reversal, review, sale, scheduled, sell, selling, separate, setup, shown, situation, spent, split, state, statement, stronger, Supplementary, tagging, threatened, threshold, tiered, Today, traditional, treatment, triaging, typically, valid, volume, written

Removed: acquirer, artificial, awarded, borrowing, Carlo, classification, classified, commencement, Committee, contractual, convergence, Cranbury, Croatia, declined, decreasing, derive, discounted, enable, expanded, expiration, faster, fixed, forfeited, forfeiture, greatest, increasing, incremental, innovative, Jersey, June, likelihood, liquid, maintained, marketable, maturity, measured, meeting, Michigan, modification, Monte, occasional, originated, pandemic, prepaid, proceeding, prolonged, rent, resulted, Rochester, science, security, shared, simulation, slower, standard, stay, subsequent, terminate, therapeutic, transient, Zagreb

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated OPRX transcripts

OPRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly Report of OptimizeRx Corp (the “Company”) on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission (the “Report”), I, Will Febbo, Chief Executive Officer and I, Edward Stelmakh, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the consolidated financial condition of the Company as of the dates presented and the consolidated result of operations of the Company for the periods presented.

By:	/s/ William J Febbo
Name:	Willian J Febbo
Title:	Principal Executive Officer

Date:	May 15, 2024

By:	/s/ Edward Stelmakh
Name:	Edward Stelmakh
Title:	Principal Financial Officer

Date:	May 15, 2024

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.